← FDA DRUG APPROVALS

FDA ANDA · ANDA206877

ACID REDUCER

omeprazole

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA206877
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-06
LATEST ACTION
2024-11-08
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Over-the-counter

Products

OMEPRAZOLE MAGNESIUMOver-the-counter
OMEPRAZOLE MAGNESIUM EQ 20MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2024-11-08Labeling · Supplement 8 · standardAP
2024-11-08Labeling · Supplement 12 · standardAP
2024-11-08Labeling · Supplement 5 · standardAP
2024-11-08Labeling · Supplement 3 · standardAP
2018-06-06UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →